Supernus Pharmaceuticals (NASDAQ:SUPN) Reaches New 12-Month High – Time to Buy?

Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)’s stock price hit a new 52-week high during trading on Monday . The stock traded as high as $35.51 and last traded at $35.51, with a volume of 200 shares changing hands. The stock had previously closed at $34.54.

Analysts Set New Price Targets

A number of brokerages recently issued reports on SUPN. Cowen reiterated a “buy” rating on shares of Supernus Pharmaceuticals in a research report on Friday. Piper Sandler reaffirmed a “neutral” rating on shares of Supernus Pharmaceuticals in a report on Friday. Finally, StockNews.com raised Supernus Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, August 7th.

Supernus Pharmaceuticals Stock Up 2.8 %

The stock has a fifty day moving average of $33.03 and a 200-day moving average of $30.29. The firm has a market capitalization of $1.96 billion, a P/E ratio of 383.78 and a beta of 0.88.

Supernus Pharmaceuticals (NASDAQ:SUPN) last announced its earnings results on Tuesday, August 6th. The specialty pharmaceutical company reported $0.36 earnings per share for the quarter, missing analysts’ consensus estimates of $0.39 by ($0.03). Supernus Pharmaceuticals had a return on equity of 0.56% and a net margin of 0.83%. The company had revenue of $168.30 million during the quarter, compared to the consensus estimate of $148.83 million. During the same period in the prior year, the firm posted ($0.02) earnings per share. The company’s revenue was up 24.1% on a year-over-year basis. As a group, analysts forecast that Supernus Pharmaceuticals, Inc. will post 1.53 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the company. Commonwealth Equity Services LLC boosted its holdings in Supernus Pharmaceuticals by 3.6% in the second quarter. Commonwealth Equity Services LLC now owns 10,195 shares of the specialty pharmaceutical company’s stock valued at $273,000 after acquiring an additional 350 shares during the last quarter. Covestor Ltd boosted its stake in Supernus Pharmaceuticals by 15.3% in the 1st quarter. Covestor Ltd now owns 2,702 shares of the specialty pharmaceutical company’s stock worth $92,000 after purchasing an additional 358 shares during the period. GAMMA Investing LLC increased its holdings in Supernus Pharmaceuticals by 97.1% during the 3rd quarter. GAMMA Investing LLC now owns 808 shares of the specialty pharmaceutical company’s stock worth $25,000 after purchasing an additional 398 shares in the last quarter. Louisiana State Employees Retirement System raised its stake in shares of Supernus Pharmaceuticals by 2.2% in the 2nd quarter. Louisiana State Employees Retirement System now owns 27,700 shares of the specialty pharmaceutical company’s stock valued at $741,000 after purchasing an additional 600 shares during the period. Finally, Texas Permanent School Fund Corp lifted its holdings in shares of Supernus Pharmaceuticals by 1.3% in the first quarter. Texas Permanent School Fund Corp now owns 47,814 shares of the specialty pharmaceutical company’s stock valued at $1,631,000 after purchasing an additional 619 shares in the last quarter.

About Supernus Pharmaceuticals

Supernus Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system (CNS) diseases in the United States. The company's commercial products are Trokendi XR, an extended release topiramate product indicated for the treatment of epilepsy, as well as for the prophylaxis of migraine headache; and Oxtellar XR, an extended release oxcarbazepine for the monotherapy treatment of partial onset seizures in adults and children between 6 to 17 years of age.